Paul Tudor Jones Neurocrine Biosciences Inc Transaction History

Tudor Investment Corp Et Al

$26.8 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $4.8 Million - $6.01 Million	-45,245 Reduced 92.68%	3,574 $470,000
Q3 2023 Nov 15, 2023	BUY	$94.02 - $117.1 $4.59 Million - $5.72 Million	48,819 New	48,819 $5.49 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $4.05 Million - $5.29 Million	-43,036 Reduced 89.56%	5,016 $508,000
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $5.13 Million - $6.11 Million	48,052 New	48,052 $5.74 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $3.01 Million - $3.97 Million	39,675 Added 1314.18%	42,694 $4.16 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $3.01 Million - $3.94 Million	-41,521 Reduced 93.22%	3,019 $283,000
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $1.2 Million - $1.6 Million	15,028 Added 50.92%	44,540 $3.79 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $469,853 - $539,911	5,452 Added 22.66%	29,512 $2.83 Million
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $2.15 Million - $2.46 Million	24,060 New	24,060 $2.34 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $2.35 Million - $3.21 Million	-26,854 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $1.03 Million - $1.29 Million	-11,898 Reduced 30.7%	26,854 $2.57 Million
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $3.73 Million - $5.24 Million	38,752 New	38,752 $3.73 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $2.14 Million - $3.25 Million	-28,537 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $2.2 Million - $3.01 Million	25,377 Added 803.07%	28,537 $3.07 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $264,871 - $320,740	3,160 New	3,160 $285,000
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $752,668 - $950,942	-10,419 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $744,320 - $982,940	-10,739 Reduced 50.76%	10,419 $918,000
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $136,640 - $248,720	-2,000 Reduced 8.64%	21,158 $1.51 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $2.29 Million - $2.91 Million	23,158 New	23,158 $2.85 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $673,257 - $947,656	-8,941 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $1.51 Million - $1.84 Million	-19,927 Reduced 69.03%	8,941 $741,000
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $1.69 Million - $2.24 Million	28,868	28,868 $2.24 Million

Others Institutions Holding NBIX

# of Institutions

631

Shares Held

93.9M

Call Options Held

632K

Put Options Held

621K

Black Rock Inc. New York, NY

14.2M
Shares

$2.08 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

10M
Shares

$1.47 Billion
0.02% of portfolio
State Street Corp Boston, MA

5.15M
Shares

$756 Million
0.02% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

2.57M
Shares

$378 Million
0.47% of portfolio
Bellevue Group Ag Kuesnacht, V8

1.86M
Shares

$274 Million
3.62% of portfolio

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account